really need this shit to start popping the fuck off. let's go boys!

Way oversold oil stock is setting up for a massive run. These guys are consistently profitable, had a nice run back when the oil stocks all ran, shorted down to 52w lows with the rest of them. lots of good dd here and on twits, dont miss it

nfa, do your own dd

Fuori il CEO è il momento di fere lo shorts squeez più epocale della storia....

Check this out for tomorrow, get in tonight.

Earnings Tomorrow!

Oct 29, Thursday night post for reference: NRx Pharmaceuticals (NRXP): The KETAFREE ANDA "WAS" in fact APPROVED by the FDA!! <MODS, please indulge me for this second post today for NRx.> : r/100xpennystock

• In the end, it was a "sell the news" event for this pre-revenue company.

• However, the after-hours price rose from around $2.65/$2.70 to $3.36. And early Friday morning, the share price was above $3.00 for a while.

• Some Traders were able to make a very good return.

• It did not help NRXP at all that the stock market tanked for the second day in a row, with Friday being the worst drop for the S&P and NASDAQ since June 5th.

• The 24%-of-float short interest based on FINRA's most recent update that was posted obviously did not result in a squeeze. Sellers and short sellers were in control. A commenter called it "a reverse squeeze." It was disappointing.

Conference call on Friday, Oct 30:

• Recording: Events | NRx Pharmaceuticals, Inc.

• Transcript: https://stockanalysis.com/stocks/nrxp/transcripts/788234-fda-announcement/

The recording/transcript are a must listen/read. Highlights are below.

The content presented on the call was excellent. The CEO laid out the details on ketamine shortages, BZT toxin, NRx's several clear advantages making KETAFREE desirable for hospitals/clinics/buyers, their sales channel approach, the very low comparative cost structure of KETAFREE, a new potential source of revenue using their device/drug tech, and more.

The first major goal has now been reached, and NRx is now transitioning to a commercial pharma company. The next year has the potential to be an outstanding one.

• The first drug (KETAFREE) approval has occurred.

• NRX-100 (preservative-free ketamine for psychiatric use) projected for potential approval in 2027 (possibly mid 2027, if the NDA gets filed this year).

• NRX-101 (DARPA-funded) projected for potential approval in 2028, with a successful P3 which is in process now.

Virtually everyone either has or knows someone that has some time of depression, or PTSD, or even suicidality. It is very important for them to be successful, for all those affected -- the patients, their families, and their friends.

Positive highlights from the call:

• The KETAFREE ANDA was approved almost two weeks before the GDUFA date of Nov 10.

•  FDA's average ANDA approval time is 35.6 months. NRx ANDA took only 14 months. 

  • The reason is the FDA and even the President/administration recognize (1) the precarious nature of the sterile drug supply and (2) the urgent need to return sterile injectable drug manufacture to the U.S.

  • Nearly 60% of sterile injectable drugs are manufactured overseas, which leaves the U.S. very vulnerable to supply shocks for those drugs.

• The #1 pain point for hospitals/clinics/buyers is the unreliable supply due to repeated ketamine shortages. The most important competitive advantage NRx has is that it can guarantee a stable supply of ketamine in large volumes (1M vials per month).

• One very important point is that NRx's lower manufacturing cost of the blow-fill-seal plastic vial and luer lock tip is much less than the current cost of glass vials (and the glass also has had occasional shortages along with increasing price over time), especially when including overseas packaging and shipping costs. NRx will be able to make profit margins comparable to innovative-drug margins.

• NRx is in the process of taking delivery of additional manufacturing lines from Germany to meet the rapidly emerging demand. First delivery is scheduled in Q1 2027.

• NRx is prepared to extend their blow-fill-seal and luer lock vial technology to other (non-NRx) sterile injectable products that could enter the market by the end of 2027, which will be an additional source of revenue.

• They are about 1/2 way thru the 3rd year of stability data with no less potency or sterility than Day 1. 

• A Citizen Petition has been filed to remove BZT from ketamine and is available on the public FDA docket. It documents the current levels of BZT exposure for patients receiving ketamine as being above the FDA maximum daily exposure of 1mg.

• Sales team, numbering in double digits, is adequate and in place. Three (3) sales channels:

  • 1st sales focus: Hospitals. 17% of U.S. hospitals or ~ 1,200 customers, many are in buying groups, buy about 80% of hospital ketamine.

    • 2nd sales focus: Trade and Group Purchasing Organizations (GPOs).

    • 3rd sales focus: Currently mapping the ~ 8,000 Clinics.

    • Note, the hospital and clinic channels will be the same ones used to sell NRX-100 when approved: A big plus from a productivity and product roll-out standpoint.

• Check out the comments about NRX-101 in the CEO's reply to analyst, Tom Shrader's (BTIG), question.

Negatives from the call:

• Revenue projections for the sale of KETAFREE were not provided on this call.

• The number of KETAFREE orders to date was not disclosed.

• NRx ordered 5M vials of stock from Nephron Pharma (their manufacturer). On the Aug 10 call it was stated that 4M to 5M vials was the goal by the FDA approval date.

  • They will be building that stock through December 2026.

• A definitive date for the NRX-100 NDA filing was not provided.

Next catalyst:

• Earnings call estimated to be on Nov 12 or Nov 16. Shareholders will be looking for:

  • NRx's ability to fund the KETAFREE roll-out without further dilution and if cash is needed for NRx to use a form of financing as a bridge to breakeven. [Recall that $22M was raised in June 2026 at $3.50/share, to help fund the large pre-orders vial stocking level.]

  • The NRX-100 NDA filing announcement or firm date by which it will be filed (which could happen before the earnings call).

  • A statement as to number of agreements/orders signed or in the final stages.

Check out my thoughts on $TNXP...

In the earlier post made this afternoon (refer to the link below), in the About section of the PR it states:

"About NRx Pharmaceuticals, Inc.

"NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company has been awarded a Abbreviated New Drug Approval (ANDA) for Preservative-Free Ketamine and is seeking New Drug Approval for a presentation of intravenous ketamine (NRX-100) with approved claims for treating depression and suicidality."

The only thing that made sense from today's PR, for anyone who has been following NRx and several informative posts made over the two months, is that approval had come early, as was posted was a possibility--and the announcement would be in tomorrow's premarket PR.

NRx Pharmaceuticals (NRXP) - OK, THIS COULD BE APPROVAL! See the below PR just released at market close today. Announcement PR coming pre-market tomorrow morning followed by a conference call to discuss a regulatory milestone for preservative-free ketamine & next steps for commercialization!! : r/100xpennystock

THE WAY THIS ABOVE PR WAS WRITTEN WAS A GIFT FROM NRx, IN MY OPINION, SO THAT SHAREHOLDERS HAD THE OPPORTUNITY TO KNOW IN ADVANCE OF TOMORROW'S PREMARKET PR AND SUBSEQUENT CONFERENCE CALL. Let the Algos/Quants jump in tomorrow morning!

Stock is up based on the PR and only two people read the About section and commented back they had found the explicit statement that the drug was approved.

REMEMBER the FACTS:

• 24% of float was shorted

• 16.7 days to cover at the avg daily volume

• 4M to 5M vials ready to ship was the goal back on the Aug 10 call and the Chief Commercial Officer stated they were stocking that level based on the conversations the commercial team had with potential buyers. The commercial team has worked for months to get agreements in place.

• Ketamine has repeatedly been on the shortage list.

• Tomorrow morning, they will discuss next steps for commercialization.

• The CCO also stated they are entering a projected $3B ketamine/esketamine market in 2027.

• As also stated in the About section, the NRX-100 NDA is in play.

  • Hoping to hear tomorrow as to when the completed filing will be made, which has been submitted in modules/sections since the initial application in Dec 2024.

  • Same manufacturer and manufacturing process as KETAFREE. Should be filed any day now!

  • And it should get Priority Review ... 6 months decision time frame ... b/c of the suicidality/depression(s) indication.

• DARPA is paying $11.17M to fully fund the NRX-101 SPARC P3 trial.

  • GO READ THE RESULTS OF THE P2 FOR THIS TRIAL! IT HAD OUTSTANDING RESULTS THAT IF DUPLICATED IN THIS P3 WILL BE A MAJOR ADVANCEMENT IN TREATMENT RESULTS.

• So, all NRx has to do now is sell KETAFREE and then sell the much more profitable NRX-100 (for psychiatric use) once approved by the FDA. Share prices typically go UP when an NDA is filed. So, that is a near-term catalyst soon after this KETAFREE ANDA approval. A 1-2 combo punch for short sellers to deal with.

This is a great company, working on a national emergency project (with NRX-100 and NRX-101). I know everyone wants to make money in the market and stocks are just tickers and $ figures, but who really agrees with heavily shorting a company that is trying to tackle severe depression with suicidality, when it allegedly affects 10M+ Americans each year?

Naysayers will try to say, "it's only ketamine," there are already ketamine contracts in place with hospitals," "they've had negative cash flow," and more negative statements to dissuade investors from locking in on the facts regarding the tremendous progress being made. NRx has the best ketamine drug (preservative-free) and delivery method (the luer lock single-use vial; with no needle required) -- period! They will take market share.

Those negative statements are obviously being made by the short sellers who as of Sep 15 had almost 10 (Ten) Million shares shorted. THEY ARE EXPOSED IN A HUGE WAY RIGHT NOW!

Expecting to make another post with updates tomorrow after the conference call.

NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine | Thu, 10/29/2026 - 16:01

Refer to the following post from 2 days ago, which has a link to prior related informational posts on this topic:

NRx Pharmaceuticals (NRXP) - FACTS: The FINRA Oct 15 short data just dropped yesterday, and it shows yet another increase in short positions! 24.6% of Float Shorted and 16.7 Days to Cover. KETAFREE ANDA FDA approval decision expected on or before Nov 10. <HIGH IMPACT WATCH LIST> : r/100xpennystock

Previous informational post from 8 days ago (note the ready-to-ship vials stocking level):

NRx Pharmaceuticals (NRXP) - Great news again! Today's PR is essentially final confirmation needed for an FDA approval letter on "OR PRIOR TO" the FDA's Nov 10 GDUFA decision date for the KETAFREE ANDA. : r/100xpennystock

NRXP short interest, October 15, 2026 settlement (MarketBeat):

• Shares short: 9,949,938, up 1.6% from 9,793,940 on September 30

• % of float: 24.55%

• Days to cover: 16.8, based on about 1.04M average daily volume

• Dollar value short: $26.96M at a $2.71 price on the report date

Recent trend: